↓ Skip to main content

Breast cancer brain metastases: the last frontier

Overview of attention for article published in Experimental Hematology & Oncology, November 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#5 of 298)
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
6 news outlets
twitter
2 tweeters
facebook
2 Facebook pages
googleplus
1 Google+ user

Citations

dimensions_citation
102 Dimensions

Readers on

mendeley
194 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Breast cancer brain metastases: the last frontier
Published in
Experimental Hematology & Oncology, November 2015
DOI 10.1186/s40164-015-0028-8
Pubmed ID
Authors

José Pablo Leone, Bernardo Amadeo Leone

Abstract

Breast cancer is a common cause of brain metastases, with metastases occurring in at least 10-16 % of patients. Longer survival of patients with metastatic breast cancer and the use of better imaging techniques are associated with an increased incidence of brain metastases. Unfortunately, patients who develop brain metastases tend to have poor prognosis with short overall survival. In addition, brain metastases are a major cause of morbidity, associated with progressive neurologic deficits that result in a reduced quality of life. Tumor subtypes play a key role in prognosis and treatment selection. Current therapies include surgery, whole-brain radiation therapy, stereotactic radiosurgery, chemotherapy and targeted therapies. However, the timing and appropriate use of these therapies is controversial and careful patient selection by using available prognostic tools is extremely important. This review will focus on current treatment options, novel therapies, future approaches and ongoing clinical trials for patients with breast cancer brain metastases.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 194 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 <1%
Egypt 1 <1%
Unknown 192 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 28 14%
Student > Bachelor 27 14%
Student > Ph. D. Student 24 12%
Student > Master 24 12%
Other 13 7%
Other 36 19%
Unknown 42 22%
Readers by discipline Count As %
Medicine and Dentistry 56 29%
Biochemistry, Genetics and Molecular Biology 20 10%
Agricultural and Biological Sciences 16 8%
Pharmacology, Toxicology and Pharmaceutical Science 11 6%
Engineering 8 4%
Other 35 18%
Unknown 48 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 47. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2022.
All research outputs
#757,258
of 23,025,074 outputs
Outputs from Experimental Hematology & Oncology
#5
of 298 outputs
Outputs of similar age
#13,916
of 387,778 outputs
Outputs of similar age from Experimental Hematology & Oncology
#1
of 5 outputs
Altmetric has tracked 23,025,074 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 298 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 387,778 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them